Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Aurora Cannabis Inc.NASDAQ: ACB
EBITDA · Q4 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q4 FY2026 EBITDA was -CA$25.18M, compared with -CA$11.43M a year earlier. Trailing-twelve-month EBITDA was CA$10.48M.
Context
- EBITDA amounted to 46.4% of revenue in FY2026, up 31.4 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -CA$2.73M (+98.2%) for the fiscal year ending Mar 2027, a step up from the -390.1% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$25.18M-393.6% QoQ
- Last fiscal yearMar 2026
- -CA$148.99M-390.1% YoY
- LTMMar 2026
- CA$10.48M-79.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -120.2% | -119.5% | +0.7 pp |
| 1 year | -390.1% | +98.2% | +488.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2026
- (148.99M) CAD
- Year-over-year change
- -390.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (148.99M) | -390.1% |
| FY2025 | 2025-03-31 | 51.35M | +516.1% |
| FY2024 | 2024-03-31 | (12.34M) | +90.9% |
| FY2023 | 2023-03-31 | (135M) | +91.3% |
| FY2022 | 2022-06-30 | (1.55B) | — |
EBITDA vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -79.6% is the 8th highest of 10, against a peer median of -19.8%.
- EBITDA amounts to 3.4% of revenue for ACB, versus a peer median of 40.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $207.13M USD | +167.4% | -26.3% | 57.3% | |
| LTM Mar 2026 | CA$10.48M CAD | -79.6% | — | 3.4% | |
| LTM Mar 2026 | CA$5.64M CAD | -19.8% | — | 2.1% | |
| LTM Mar 2026 | -$1.03M USD | — | — | 0.8% | |
| LTM Mar 2026 | -$4.22M USD | -227.5% | — | 1.9% | |
| LTM Apr 2026 | -CA$6.09M CAD | -121.9% | — | 0.9% | |
| LTM Mar 2026 | -$9.96M USD | +38.2% | — | 23.8% | |
| LTM Mar 2026 | -$70.61M USD | -31.5% | — | 843.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M USD | -28.4% | — | 864.8% |
| LTM Mar 2026 | -$100.08M USD | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -CA$205.34M CAD | +57.2% | — | 65.7% | |
| Peer median (excluding ACB) | — | -19.8% | -26.3% | 40.6% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 221.34M | 223.8M | 270.28M | 343.29M | 321.42M |
| Cost of Revenue | 200.11M | 209.02M | 138.82M | 155.69M | 304.67M |
| Gross Profit | 21.23M | 14.78M | 131.46M | 187.61M | 16.75M |
| Gross Margin | 9.6% | 6.6% | 48.6% | 54.6% | 5.2% |
| Research & Development | 10.39M | 5.77M | 3.57M | 3.68M | 6.01M |
| Selling, General & Admin | 188.99M | 170.48M | 156.88M | 166.47M | 173.95M |
| Operating Expenses | 252.67M | 221.98M | 177.91M | 182.66M | 179.96M |
| Depreciation & Amortization | 93.66M | 52.59M | 33.07M | 22.55M | 14.23M |
| EBITDA | (1.55B) | (135M) | (12.34M) | 51.35M | (148.99M) |
| EBITDA Margin | -702.4% | -60.3% | -4.6% | 15.0% | -46.4% |
| Operating Income | (231.45M) | (207.19M) | (46.45M) | 4.95M | (163.21M) |
| Operating Margin | -104.6% | -92.6% | -17.2% | 1.4% | -50.8% |
| Interest Income | 4.51M | 19M | 12.81M | 11.51M | 5.86M |
| Interest Expense | 71.81M | 39.46M | 14.19M | 8.42M | 1.81M |
| Other Income / Expenses | (1.49B) | (576.51M) | (13.15M) | 15.43M | 106.54M |
| Income Before Tax | (1.72B) | (783.7M) | (59.6M) | 20.38M | (56.67M) |
| Pre-Tax Margin | -777.1% | -350.2% | -22.1% | 5.9% | -17.6% |
| Income Tax Expense | (2.14M) | 16.55M | (554K) | 4.62M | 2.1M |
| Net Income | (1.72B) | (816.63M) | (69.33M) | 1.59M | (122.07M) |
| Net Margin | -776.0% | -364.9% | -25.6% | 0.5% | -38.0% |
| EPS (Basic) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| EPS (Diluted) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| Weighted Avg Shares | 21.49M | 32.27M | 51.26M | 54.88M | 56.71M |
| Weighted Avg Shares (Diluted) | 21.49M | 32.27M | 51.26M | 55.75M | 56.71M |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.